

Company Name: SOPHARMA AD

Board of Directors: Ognian Donev, PhD
Vessela Stoeva
Alexander Tchaushev
Ognian Palaveev
Andrey Breshkov

Executive Director: Ognian Donev, PhD

Finance Director: Boris Borisov

Chief Accountant: Yordanka Petkova

Head of Legal Department: Galina Angelova

Address of Management: Sofia
16, Iliensko Shousse Str.

Lawyers: Adriana Baleva
Venelin Gachev
Ventsislav Stoev
Lyubimka Georgieva
Stefan Yovkov
Rositsa Kostadinova
Tsonka Taushanova
Petar Kalpakchiev

Servicing Banks: Raiffeisenbank (Bulgaria) EAD
DSK Bank EAD
Eurobank and EFG Bulgaria AD
ING Bank NB
Unicredit AD
Societe General Expressbank AD
Citibank N.A.
Cibank EAD

Auditor: AFA OOD

INDIVIDUAL STATEMENT OF COMPREHENSIVE INCOME

for the period ended 31 December 2015

	Notes	2015 BGN'000	2014 BGN'000
Sales revenues	3	173 960	201 461
Other operating revenue/(loss), net	4	4 153	3 973
Change of available stock of finished goods and work in progress		2 448	14 039
Materials	5	(61 660)	(73 920)
External services	6	(41 400)	(56 396)
Employees	7	(35 782)	(37 605)
Amortization	14,15	(14 860)	(16 989)
Other operating expenses	8,9	(5 529)	(9 902)
Operating profit		21 330	24 661
Impairment of non-current assets	10	(8 992)	(3 252)
		(8 992)	(3 252)
Financial income	11	17 921	13 001
Financial expenses	12	(4 190)	(4 690)
Financial income/(expenses) net		13 731	8 311
Profit before tax		26 069	29 720
Profit tax		(3 800)	(2 429)
Net profit for the year		22 269	27 291
Other components of the total income:			
<i>Components that will not be reclassified in the profit or loss:</i>			
Subsequent valuation of pension plans with defined benefit		(51)	(310)
Loss from revaluation of property, plant and equipment		-	(6)
Tax on income, related to other components of comprehensive income, which will not be reclassified		-	1
		(51)	(315)
<i>Components that may be reclassified in the profit or loss:</i>			
Net change in fair value of available-for-sale financial assets		109	113
		109	113
Other comprehensive income for the period net of tax	13	58	(202)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		22 327	27 089
Earnings per share		0.17	0.22

The notes on pages 5 to 100 are an integral part of the present financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant (preparer):

Iordanka Petkova

SOPHARMA AD
INDIVIDUAL STATEMENT OF FINANCIAL POSITION
as at 31 December 2015

	Attachments	31 December 2015 BGN'000	31 December 2015 BGN'000
ASSETS			
Non-current assets			
Property, plant and equipment	14	210 620	211 056
Intangible assets	15	2 303	3 210
Investment properties	16	22 160	22 368
Investments in subsidiaries	17	133 810	94 434
Investments in associated companies	18	-	7 015
Available-for-sale investments	19	5 425	4 439
Long-term receivables from related parties	20	20 505	33 150
Other long-term receivables	21	3 258	6
		398 081	375 678
Current assets			
Inventories	22	57 292	57 360
Receivables from related persons	23	80 063	99 505
Commercial receivables	24	21 457	23 397
Other receivables and prepayments	25	6 520	11 901
Cash and cash equivalents	26	3 911	4 076
		169 243	196 239
TOTAL ASSETS		567 324	571 917
EQUITY AND LIABILITIES			
EQUITY			
Share capital		134 798	132 000
Treasury shares		(17 597)	(17 203)
Premium reserve		8 785	-
Reserves		275 358	246 243
Retained earnings		27 113	45 484
	27	428 457	406 524
LIABILITIES			
Non-current liabilities			
Long-term bank loans	28	30 819	37 972
Deferred taxes		5 161	4 124
Government financing	29	6 371	3 968
Long-term payables to personnel	30	2 571	2 387
Financial leasing liabilities	31	3	34
		44 925	48 485
Current liabilities			
Short-term bank loans	32	68 961	90 761
Short-term part of long-term bank loans	28	7 380	7 431
Payables to related parties	33	8 051	7 909
Commercial payables	34	1 609	4 154
Tax payables	35	1 821	938
Payables to employees and social insurance	36	4 618	4 564
Other current liabilities	37	1 502	1 151
		93 942	116 908
TOTAL LIABILITIES		138 867	165 393
TOTAL EQUITY AND LIABILITIES		567 324	571 917

The notes on pages 5 to 100 are an integral part of the present financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant (preparer):

Iordanka Petkova

SOPHARMA AD
INDIVIDUAL STATEMENT OF CASH FLOWS
for the period ended 31 December 2015

	Attachments	2015 BGN'000	2014 BGN'000
Cash flows from operating activities			
Sales proceeds		185 756	217 550
Payments to suppliers		(119 617)	(138 665)
Payments for wages and social insurance		(33 936)	(35 583)
Taxes paid (profit tax excluded)		(5 891)	(6 310)
Taxes refunded (profit tax excluded)		4 727	3 615
Profit tax paid		(758)	(4 938)
Paid interest and bank fees on working capital loans		(2 519)	(3 015)
Exchange rate differences, net		45	(132)
Other proceeds/(payments), net		760	(989)
Net cash flows from/(used in) operating activities		28 567	31 533
Cash flows from investing activities			
Purchase of property, plant and equipment		(9 125)	(8 766)
Proceeds from sale of property, plant and equipment		134	335
Purchase of intangible assets		(29)	(50)
Purchase of investment properties		-	(1 005)
Purchase of shares in associated companies		(14 818)	(3 136)
Proceeds from sale of shares in associated companies		2	-
Purchase of available-for-sale investments		(1 451)	(1 425)
Proceeds from sale of available-for-sale investments		474	133
Purchase of shares in subsidiaries		(2 676)	(5 988)
Proceeds from sale of shares in subsidiaries		3 399	5 046
Loans granted to related parties		(14 297)	(19 480)
Repaid loans, granted to related parties		28 787	12 555
Loans granted to third parties		(2 232)	(518)
Repaid loans, granted to third parties		856	362
Proceeds from dividends from investments in subsidiaries		7 837	6 332
Received interest on granted loans and deposits		2 727	3 587
Net cash flows used in investing activities		(412)	(12 018)
Cash flows from finance activities			
Settlement of long-term bank loans		(7 226)	(7 683)
Proceeds from short-term bank loans (overdraft), net		3 361	5 327
Settlement of short-term bank loans (overdraft), net		(25 175)	(13 328)
Paid interest and bank fees on investment purpose loans		(1 208)	(1 661)
Received donations from public companies		3 000	-
Proceeds from sales of treasury shares		-	2 784
Treasury shares		(394)	(1 263)
Dividends paid		(10)	(8 811)
Finance lease payments		(70)	(95)
Net financial cash flows		(27 722)	(24 730)
Net (decrease)/increase in cash and cash equivalents		433	(5 215)
Cash and cash equivalents at 1 January		3 478	8 693
Cash and cash equivalents at 31 December	26	3 911	3 478

The notes on pages 5 to 100 are an integral part of the present financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant (preparer):

Iordanka Petkova

SOPHARMA AD

INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

for the period ended 31 December 2015

	Attachment	Share capital BGN'000	Treasury shares BGN'000	Statutory reserves BGN'000	Revaluation reserve - BGN'000	Available-for-sale financial BGN'000	Premium reserve BGN'000	Additional reserves BGN'000	Retained earnings BGN'000	Total equity BGN'000
Balance at 1 January 2014 (originally stated)		132 000	(18 105)	-	30 051	23 392	984	166 508	35 905	370 735
Effect from mergers with subsidiaries	27	-	-	-	-	-	-	-	16 069	16 069
Balance at 1 January 2014 (recalculated)		132 000	(18 105)	-	30 051	23 392	984	166 508	51 974	386 804
Changes in equity in 2014										
Effect from purchase of treasury shares		-	902		-	-	-	-	619	1 521
Distribution of profit for:		-	-	-	3 504	-	-	22 649	(35 043)	(8 890)
* reserves		-	-		3 504	-	-	22 649	(26 153)	-
* dividends		-	-		-	-	-	-	(8 890)	(8 890)
Total comprehensive income for the year (originally stated)		-	-	-	-	(5)	113	-	26 232	26 340
Effect from mergers with subsidiaries	27	-	-	-	-	-	-	-	749	749
Total comprehensive income for the year (recalculated), incl.:		-	-	-	-	(5)	113	-	26 981	27 089
* net profit for the year		-	-		-	-	-	-	27 291	27 291
* other component of comprehensive income, net of taxes		-	-		-	(5)	113	-	(310)	(202)
Transfer to retained earnings		-	-		-	(953)	-	-	953	-
Balance at 31 December 2014 (originally stated)	27	132 000	(17 203)	-	33 555	22 434	1 097	189 157	28 666	389 706
Effect from mergers with subsidiaries		-	-	-	-	-	-	-	16 818	16 818
Balance at 31 December 2014 (recalculated)		132 000	(17 203)	-	33 555	22 434	1 097	189 157	45 484	406 524
Changes in equity in 2015										
Effect from mergers with subsidiaries	27	2 798		8 785		344			(11 927)	-
Effect from purchase of treasury shares		-	(394)		-	-	-	-		(394)
Distribution of profit for:		-	-	-	2 916	-	-	26 238	(29 154)	-
* reserves		-	-		2 916	-	-	26 238	(29 154)	-
Total comprehensive income for the year, incl.:		-	-	-	-	-	109	-	22 218	22 327
* net profit for the year		-	-		-	-	-	-	22 269	22 269
* other component of comprehensive income, net of taxes		-	-		-	-	109	-	(51)	58
Transfer to retained earnings		-	-		-	(492)	-	-	492	-
Balance at 31 December 2015	27	134 798	(17 597)	8 785	36 471	22 286	1 206	215 395	27 113	428 457

The notes on pages 5 to 100 are an integral part of the present financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant (preparer):

Iordanka Petkova